This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Solid Organ Transplantation
  • /
  • Everolimus in de Novo Kidney Transplant Recipients...
Clinical trial

Everolimus in de Novo Kidney Transplant Recipients (NEVERWOUND)

Read time: 1 mins
Last updated:15th Jun 2017
Identifier: NCT01410448
Everolimus in de Novo Kidney Transplant Recipients (NEVERWOUND)

The purpose of this study was to evaluate whether delayed (i.e. 28 ± 4 days post-transplant) administration of everolimus after transplantation reduces the risk of wound healing complications in comparison with immediate administration in de novo renal transplant patients (proportion of patients without wound/surgical complications related to initial transplant surgery) between randomization and 3 months after transplantation.

Study Type: Interventional (Clinical Trial)
Actual Enrollment: 383 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A 3-month, Multicenter, Randomized, Open Label Study to Evaluate the Impact of Early Versus Delayed Introduction of Everolimus on Wound Healing in de Novo Kidney Transplant Recipients With a Follow-up Evaluation at 12 Month After Transplant (NEVERWOUND Study)
Study Start Date: November 2011
Actual Primary Completion Date: December 2015
Actual Study Completion Date: December 2015

- Active Comparator: Immediate Everolimus (IE)
- Experimental: Delayed Everolimus

Category Value
Study type(s) Interventional
Expected enrolment 383
Study start date 1 November 2011
Estimated primary completion date 1 December 2015

View full details